DVSSciences Inc.

FUNDING AND ACHIEVEMENTS

The proof-of-principle work on the instrument and reagents development was largely funded by Genome Canada via the Ontario Genomics Institute, with additional support from the Ontario Ministry of Research and Innovation and the Ontario Institute for Cancer Research, and complementary support from various Foundations and Companies.

Between 2005 and 2008 the project was supported by funding of $4.5 million with an additional $3.3 million that supported collaborating parties at the University Health Network and McMaster University.

Support through early 2010 includes an additional $2.8M over two years for work at the University of Toronto.

The UofT work has further benefited from $500K provided by the US NIH through the IMAT program.

In addition, DVS Sciences has received an investment of $500K from the Ontario Institute for Cancer Research (See News), and supports its own development efforts through proceeds of sales of MAXPAR™ reagents and CyTOF™ instruments.

A recent grant from HTX (the Ontario Health Exchange) will support further development of the CyTOF™ sample introduction system at UofT.

Additional complementary support has been provided by several government and commercial entities including the Ontario Centres of Excellence, Ontario Cancer Research Network, National Institutes of Health, MDS Sciex, Oerlikon Leybold Vacuum, Parker Life Sciences, SGE, and MKS.

PRINCIPAL SPONSORS at U of T

Genome Canada

Ontario Genomics Institute

Ontario Institute for Cancer Research

The Health Technology Exchange

MOVING FORWARD

We are seeking:

VENTURE CAPITALISTS
Who share our enthusiasm and wish to participate in our success

COMPANIES and PARTNERS
That will provide manufacturing facilities and marketing capabilities

RESEARCH COLLABORATORS
That will complement our expertise

CONTACT US
70 Peninsula Crescent , Richmond Hill
Ontario , Canada , L4S 1Z5
1 416 946-8850 , scott.tanner@DVSsciences.com

"Some men see things as they are and say 'Why?'"
"I dream things that never were and say 'Why Not?'"

Robert F. Kennedy, paraphrasing
George Bernard Shaw

2010	January 13th, 2010 – Dr. Morris (Mickey) Milner, President and CEO of The Health TechnologyExchange (HTX), today announced the investment of over $1.7 million towards the development of seven emerging medical technologies.
2009	November, 2009 – Scott Tanner presented at the "Future of Medicine" conference.
2009	Toronto, November 17, 2009 – Marking the culmination of six years of technology development research funded by Genome Canada through the Ontario Genomics Institute (OGI) and others, a Toronto research team unveiled a first-in-class analytical instrument at the recent Great Lakes International Imaging and Flow Cytometry Association annual meeting in Pittsburgh. The CyTOF™ Mass Cytometer, being made and marketed by DVS Sciences (Toronto), was developed by a team led by Dr. Scott Tanner (University of Toronto, and co-founder and CEO of DVS Sciences).
2009	On January 20, 2009 the US patent office issued patent # 7,479,630 entitled “Method and Apparatus for Flow Cytometry Linked with Elemental Analysis”.
2008	DVS Sciences receives exclusive licenses to the technologies underpinning the CyTOF™ and MAXPAR™ product lines from MDS Sciex (Analytical Technologies) and the University of Toronto, including 54 patents and applications in 11 patent families.
2008	Toronto, July 21, 2008 – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced the investment of $500,000 in DVS Sciences Inc., for novel technology to facilitate the identification of biomarkers to study and diagnose cancer.
2008	Genome Canada Technology Development project "Massively Multiparametric Flow Cytometer Analyzer" awarded; engineering team transitions from the University to DVS Sciences Inc.; sale of first CyTOF™ prototype and first MAXPAR™ labeling kits; first 22-parameter analysis of individual cells in human blood samples conducted on Zero-phase prototype CyTOF™; Ontario Institute for Cancer Research invests in DVS Sciences, supports program to develop "Flow Cytometer-Mass Spectrometer for Multi-parametric Cell and Bead Analysis" ; relevant IP from MDS Analytical Technologies and the University of Toronto are licensed into DVS; breakthrough technological advances are published in prime scientific journals (see Publications Page)
2007	First simultaneous 20-antigen solution assay characterization of patient leukemia samples, first 8-plex single-cell assay. Market research completed (report available). Zero-phase prototype assembled and tested. Further publications (See Publications Page, Synthesis of metal-tagged polymer tags Lou et al, Angew. Chemie). Patents on Quantitation of cellular DNA and cell numbers and cell size using elemental labelling; Element-tagged oligonucleotide gene expression analysis; Post-translational modification identified by elemental analysis; Apparatus and method for elemental analysis of particles by mass spectrometry are applied for.
2006	On November 14, 2006 the US patent office issued patent # 7,135,296 entitled “Elemental Analysis of Tagged Biologically Active Materials”.
2006	First single-cell multiple antigen assay on the research breadboard; simultaneous 13-antigen solution assay; second generation of MAXPAR™ reagents is developed; zero-phase CyTOF™ prototype is designed; independent market survey initiated. Further publications (See Publications Page, Ornatsky et al, J. Immunol. Meth. 2006, Transl. Oncogenom. 2006). US patent on Elemental Analysis of Tagged Biologically Active Materials issued.
2005	DVS principals move to University of Toronto; the StemSpec laboratory is established; first mass spectra collected on the research breadboard of CyTOF™; feasibility of the first generation of the MAXPAR™ reagents is demonstrated.
2004	Genome Canada Grant awarded. DVS Sciences founded.
2003	Application to compete for Genome Canada Grant on the project "Mass-Spectrometry Based Flow Cytometry: Methods and Applications".
2002	First publications on simultaneous ICP-MS detection of antigens via elemental tagging of antibodies (See Publications Page, Baranov et al, Analytical Chemistry 2002, J. Anal. Atomic Spectrom. 2002).
2001	February : Results on simultaneous detection of antigens with antibodies labeled with elements are presented at an international conference (See Publications Page, Baranov et al, 2001, in Selected Conference Presentations).
2000	Concept of using elemental tags for immuno-detection of antigens emerges, first experimental feasibility studies conducted; initial patent application filed.